WuXi AppTec(SH:603259) Xiangcai Securities·2026-01-25 09:04Investment Rating - The report maintains a "Buy" rating for the medical services industry [5] Core Insights - The medical services sector has shown a decline of 2.17% this week, with a current PE ratio of 35.30X and a PB ratio of 3.58X, indicating a slight decrease from the previous week [3][27] - The J.P. Morgan Healthcare Conference highlighted an optimistic outlook for the CXO industry, transitioning from scale competition to value competition driven by advanced technology and global supply chains [4][59] - The report emphasizes the importance of supply chain resilience and innovative therapies as key growth drivers, particularly in the ADC CDMO sector [4][59] Summary by Sections Industry Performance - The pharmaceutical and biological sector declined by 0.39%, ranking 27th among 31 primary industries, while the Shanghai Composite Index fell by 0.62% [1][10] - The medical services sub-sector reported a significant drop, closing at 7280.46 points [21] Company Performance - Notable performers in the medical services sector include: - Nuohe Zhiyuan (+11.5%) - New Mileage (+9.4%) - Dean Diagnostics (+8.2%) - Underperformers include: - Boteng Co. (-6.9%) - Chengda Pharmaceutical (-6.6%) - WuXi AppTec (-6.4%) [2][24] Valuation Metrics - The medical services sector's PE ratio is currently at 35.30X, with a one-year maximum of 41.13X and a minimum of 28.46X; the PB ratio stands at 3.58X, with a maximum of 4.00X and a minimum of 2.48X [3][27] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO within the pharmaceutical outsourcing services, recommending companies like WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics [5][61] - It also highlights potential improvements in profitability for third-party testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [5][61]